S. 4189, the INSULIN Act of 2026, advanced out of committee on July 22, 2026.
S. 4189 — INSULIN Act of 2026
What it does
The INSULIN Act of 2026 addresses insulin affordability and market competition through four main mechanisms: (1) it restricts citizens' ability to sue the FDA over drug approvals by requiring them to first file administrative petitions with strict 60-day deadlines, and dismisses lawsuits that bypass this process; (2) it accelerates FDA review of biosimilar insulin products when fewer than 3 competitors exist; (3) it funds a 5-year pilot program in 10 high-need states to help uninsured individuals access insulin at $35/month or less; and (4) it establishes a resource center and hotline to connect uninsured patients with manufacturer assistance programs.
Quorum's transparency scan gave INSULIN Act of 2026 a high transparency warning.
What happens next
S. 4189 advanced out of committee. Next stop: a floor vote.
Who is behind it
Filed by Jeanne Shaheen. Cosponsored by Angela Alsobrooks, Angus King, Catherine Cortez Masto and Christopher Coons.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.